1、vnovotech-APRIL 11,2024Epilepsy-Global Clinical Trial Landscape(2024)The Asia-Pacific region shows shorter recruit-ment durations and faster recruitment rates compared to Europe and the USEpilepsy is a chronic neurologi-cal disorder character-ized by recurrent seizuresIdiopathic generalized epilepsy

2、 is the most common typeSmall molecule drugs like Likozam and Fycompa targeting the AMPA glutamate receptor(GRIA/GLUR),are approved for epilepsy treatmentPhase III pipeline drugs include Ztalmy and Ganaxolone(CCD-1042),targeting the GABA A receptor,suggesting advancements in epilepsy treatment optio

3、nsThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotec

4、h except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distrib

5、ution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?In the Asia-Pacific region,India reported the highest epilepsy prevalence followed by ChinaThe Unite

6、d States reported the highest number of epilepsy cases in North AmericaIn Europe,Germany and France reported a relatively higher prevalence of epilepsyIn ROW,Brazil reported the highest number of epilepsy cases10%ROW55%NORTH AMERICA&EUROPE35%ASIA-PACIFICIn 2016,epilepsy afected around 46 million peo